PURPOSE: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. PATIENTS AND METHODS: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. RESULTS: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade >or=2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade >or=2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. CONCLUSIONS: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.
PURPOSE: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. PATIENTS AND METHODS: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. RESULTS: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade >or=2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade >or=2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. CONCLUSIONS: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.
Authors: Jatinder R Palta; James A Deye; Geoffrey S Ibbott; James A Purdy; Marcia M Urie Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Andrea Molineu; David S Followill; Peter A Balter; William F Hanson; Michael T Gillin; M Saiful Huq; Avraham Eisbruch; Geoffrey S Ibbott Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Gary A Ezzell; James M Galvin; Daniel Low; Jatinder R Palta; Isaac Rosen; Michael B Sharpe; Ping Xia; Ying Xiao; Lei Xing; Cedric X Yu Journal: Med Phys Date: 2003-08 Impact factor: 4.071
Authors: D M Brizel; T H Wasserman; M Henke; V Strnad; V Rudat; A Monnier; F Eschwege; J Zhang; L Russell; W Oster; R Sauer Journal: J Clin Oncol Date: 2000-10-01 Impact factor: 44.544
Authors: Avraham Eisbruch; Lon H Marsh; Laura A Dawson; Carol R Bradford; Theodoros N Teknos; Douglas B Chepeha; Francis P Worden; Susan Urba; Alexander Lin; Matthew J Schipper; Gregory T Wolf Journal: Int J Radiat Oncol Biol Phys Date: 2004-05-01 Impact factor: 7.038
Authors: K S Clifford Chao; Gokhan Ozyigit; Angel I Blanco; Wade L Thorstad; Joseph O Deasy; Bruce H Haughey; Gershon J Spector; Donald G Sessions Journal: Int J Radiat Oncol Biol Phys Date: 2004-05-01 Impact factor: 7.038
Authors: Jeffrey S Souris; Shih-Hsun Cheng; Charles Pelizzari; Nai-Tzu Chen; Patrick La Riviere; Chin-Tu Chen; Leu-Wei Lo Journal: Appl Phys Lett Date: 2014-11-20 Impact factor: 3.791
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544